Compare Rubrik Inc. Class A Common Stock (RBRK) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rubrik Inc. Class A Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? Rubrik Inc. Class A Common Stock trades at $109.84 (market cap $24.56B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Rubrik Inc. Class A Common Stock is far larger — about 5× Travere Therapeutics Inc. Common Stock's market cap, and Rubrik Inc. Class A Common Stock is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rubrik Inc. Class A Common Stock for 4 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| RBRK | TVTX | |
|---|---|---|
Market Cap | $24.56B | $4.88B |
Volume | 2,289,465 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $125.80 | $67.52 |
52-Week Low | $43.81 | $26.79 |
Typical Hold Time | 4 Days | 0 Days |
Enterprise Value | $23.96B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rubrik (RBRK) trades at $118.47, down 1.28% on the day, with strong technical momentum showing bullish moving averages and support at $118. The company demonstrates impressive revenue growth, with 2026 revenue reaching $1.5B and recent earnings beats, though profitability remains negative with a -16.5% net margin. Recent news highlights expansion of AI security offerings including Rubrik Code Guardian and strong institutional buying interest.
Rubrik presents a compelling growth story in cybersecurity with 100% analyst buy ratings and $105.08 consensus target, though current price exceeds this. Key risks include persistent losses despite revenue growth and competitive AI security landscape. The stock's technical strength and AI-driven demand create upside potential, but profitability concerns warrant careful monitoring of margin improvement.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Rubrik Inc. Class A Common Stock
Rubrik provides data security and cyber recovery software for enterprises. Its platform protects data across on-premises, cloud, SaaS, and unstructured-data environments.
Read more on RBRK →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
